Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2012 (2012), Article ID 935921, 6 pages
http://dx.doi.org/10.1155/2012/935921
Clinical Study

Combination Therapy of Interferon Beta-1b and Tacrolimus: A Pilot Safety Study

1Division of Neurology, CSSSG-Hull Pavillion, Clinique Neuro-Outaouais, 147 Boulevard d'Europe, Gatineau, QC, Canada J9J A05
2Research Institute, Children's Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, ON, Canada K1H 8L1
3Division of Neurology, Ottawa Hospital, Nepean Medical Center, 1 Centrepointe Drive, Suite 407, Ottawa, ON, Canada K2G 6E2
4Division of Neurology, Charles Lemoynes Hospital Montreal, Clinique Neuro Rive-Sud, 4896 Boulevard Taschereau, Suite 250, Greenfield Park, QC, Canada J4V 2J2

Received 22 March 2012; Revised 10 June 2012; Accepted 3 July 2012

Academic Editor: H. P. Hartung

Copyright © 2012 F. Jacques et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Bar-Or, “The immunology of multiple sclerosis,” Seminars in Neurology, vol. 28, no. 1, pp. 29–45, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Boggild, “Rationale and experience with combination therapies in multiple sclerosis,” Journal of Neurology, vol. 253, no. 6, pp. VI/45–VI/51, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. R. L. Knobler, J. I. Greenstein, K. P. Johnson et al., “Systemic recombinant human interferon-β treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up,” Journal of Interferon Research, vol. 13, no. 5, pp. 333–340, 1993. View at Google Scholar · View at Scopus
  4. The IFNB Multiple Sclerosis Study Group, “Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial,” Neurology, vol. 43, no. 4, pp. 655–661, 1993. View at Publisher · View at Google Scholar
  5. D. W. Paty and D. K. B. Li, “Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo- controlled trial,” Neurology, vol. 43, no. 4, pp. 662–667, 1993. View at Google Scholar · View at Scopus
  6. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, “Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial,” Neurology, vol. 45, no. 7, pp. 1277–1285, 1995. View at Google Scholar · View at Scopus
  7. C. M. Spencer, K. L. Goa, and J. C. Gillis, “Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation,” Drugs, vol. 54, no. 6, pp. 925–975, 1997. View at Google Scholar · View at Scopus
  8. S. L. Schreiber and G. R. Crabtree, “The mechanism of action of cyclosporin A and FK506,” Immunology Today, vol. 13, no. 4, pp. 136–142, 1992. View at Google Scholar · View at Scopus
  9. M. J. Tocci, D. A. Matkovich, K. A. Collier et al., “The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes,” Journal of Immunology, vol. 143, no. 2, pp. 718–726, 1989. View at Google Scholar · View at Scopus
  10. H. Uchino, R. Minamikawa-Tachino, T. Kristián et al., “Differential neuroprotection by cyclosporin A and FK506 following ischemia corresponds with differing abilities to inhibit calcineurin and the mitochondrial permeability transition,” Neurobiology of Disease, vol. 10, no. 3, pp. 219–233, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Woo, C. S. K. Ross, J. I. Milton, and A. W. Thomson, “Immunosuppressive activity of FK-506 in rats; flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal,” Clinical and Experimental Immunology, vol. 79, no. 1, pp. 109–114, 1990. View at Google Scholar · View at Scopus
  12. J. Woo, H. F. Sewell, and A. W. Thomson, “The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis,” Scandinavian Journal of Immunology, vol. 31, no. 3, pp. 297–304, 1990. View at Google Scholar · View at Scopus
  13. J. Sharkey, P. A. Jones, J. F. McCarter, and J. S. Kelly, “Calcineurin inhibitors as neuroprotectants: focus of tacrolimus and cyclosporin,” CNS Drugs, vol. 13, no. 1, pp. 1–13, 2000. View at Google Scholar · View at Scopus
  14. B. G. Gold, J. Voda, X. Yu, G. McKeon, and D. N. Bourdette, “FK506 and a nonimmunosuppressant derivative reduce axonal and myelin damage in experimental autoimmune encephalomyelitis: neuroimmunophilin ligand-mediated neuroprotection in a model of multiple sclerosis,” Journal of Neuroscience Research, vol. 77, no. 3, pp. 367–377, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. M. S. Wang and B. G. Gold, “FK506 increases the regeneration of spinal cord axons in a predegenerated peripheral nerve autograft,” Journal of Spinal Cord Medicine, vol. 22, no. 4, pp. 287–296, 1999. View at Google Scholar · View at Scopus
  16. M. S. Wang, M. Zeleny-Pooley, and B. G. Gold, “Comparative dose-dependence study of FK506 and cyclosporin A on the rate of axonal regeneration in the rat sciatic nerve,” Journal of Pharmacology and Experimental Therapeutics, vol. 282, no. 2, pp. 1084–1093, 1997. View at Google Scholar · View at Scopus
  17. H. Yoshikawa, K. Iwasa, K. Satoh, and M. Takamori, “FK506 prevents induction of rat experimental autoimmune myasthenia gravis,” Journal of Autoimmunity, vol. 10, no. 1, pp. 11–16, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. J. McMichael, R. Lieberman, J. McCauley, W. Irish, I. Marino, and H. Doyle, “Computer-guided randomized concentration-controlled trials of tacrolimus in autoimmunity: multiple sclerosis and primary biliary cirrhosis,” Therapeutic Drug Monitoring, vol. 18, no. 4, pp. 435–437, 1996. View at Publisher · View at Google Scholar · View at Scopus
  19. “PROGRAF prescribing information,” August 2009.
  20. W. I. McDonald, A. Compston, G. Edan et al., “Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis,” Annals of Neurology, vol. 50, no. 1, pp. 121–127, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. “BETASERON Prescribing information,” May 2010.